Literature DB >> 11169957

Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.

C Wallrapp1, S Hähnel, W Boeck, A Soder, A Mincheva, P Lichter, G Leder, F Gansauge, C Sorio, A Scarpa, T M Gress.   

Abstract

In a study for the identification of genomic alterations in pancreatic cancer, representational difference analysis was used and led to the isolation of 2 distinct fragments, deleted on the Y chromosome in the xenografted tumor DNA of a male patient with an adenocarcinoma of the pancreas. Loss of Y chromosomal material was further studied in 11 pancreatic cancer cell lines of male origin, using PCR amplification of 5 sequence tagged sites (STSs) distributed along the Y chromosome; 8/11 cell lines exhibited a complete loss of the Y chromosome and 3 had deletions. To examine the status of the Y chromosome in situ, interphase FISH analysis was performed on paraffin sections from pancreatic carcinoma (n=7) and chronic pancreatitis (n=7) tissues, and the loss of Y-chromosomal STS-markers was studied in 6 xenograft tumors obtained from male pancreatic cancer patients. This analysis revealed that a loss of the Y chromosome occurs in vivo in primary pancreatic tumor cells, whereas the Y chromosome was intact in chronic pancreatitis. Our data suggest that loss of Y is a frequent event occurring in male pancreatic tumors. Although there is no evidence for a functional implication of Y chromosome loss, it effectively differentiates between a malignant and a benign condition as e.g. chronic pancreatitis. Thus, this genetic alteration may be of diagnostic use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169957     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1014>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

2.  Microchimeric Cells, Sex Chromosome Aneuploidies and Cancer.

Authors:  Deniz Taştemir Korkmaz; Osman Demirhan; Deniz Abat; Bülent Demirberk; Erdal Tunç; Sedat Kuleci
Journal:  Pathol Oncol Res       Date:  2015-05-24       Impact factor: 3.201

3.  Identification of specific Y chromosomes associated with increased prostate cancer risk.

Authors:  Lisa A Cannon-Albright; James M Farnham; Matthew Bailey; Frederick S Albright; Craig C Teerlink; Neeraj Agarwal; Robert A Stephenson; Alun Thomas
Journal:  Prostate       Date:  2014-05-06       Impact factor: 4.104

4.  Y Chromosome LncRNA Are Involved in Radiation Response of Male Non-Small Cell Lung Cancer Cells.

Authors:  Tayvia Brownmiller; Jamie A Juric; Abby D Ivey; Brandon M Harvey; Emily S Westemeier; Michael T Winters; Alyson M Stevens; Alana N Stanley; Karen E Hayes; Samuel A Sprowls; Amanda S Gatesman Ammer; Mackenzee Walker; Erik A Bey; Xiaoliang Wu; Zuan-Fu Lim; Lin Zhu; Sijin Wen; Gangqing Hu; Patrick C Ma; Ivan Martinez
Journal:  Cancer Res       Date:  2020-07-02       Impact factor: 12.701

5.  Loss of Y chromosome in the malignant peripheral nerve sheet tumor of a patient with Neurofibromatosis type 1.

Authors:  Seon-Yong Jeong; Sang-Jin Park; Su-Jin Lee; Ho-Jin Park; Hyon J Kim
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

6.  JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.

Authors:  Na Li; Shilpa S Dhar; Tsai-Yu Chen; Pu-Yeh Kan; Yongkun Wei; Jae-Hwan Kim; Chia-Hsin Chan; Hui-Kuan Lin; Mien-Chie Hung; Min Gyu Lee
Journal:  Cancer Res       Date:  2016-01-08       Impact factor: 12.701

Review 7.  Sexual dimorphism in solid and hematological malignancies.

Authors:  Isabel Ben-Batalla; María Elena Vargas-Delgado; Lara Meier; Sonja Loges
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

8.  Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease.

Authors:  Talia Golan; Chani Stossel; Michael Schvimer; Dikla Atias; Sharon Halperin; Ella Buzhor; Maria Raitses-Gurevich; Keren Cohen; Sara Pri-Chen; Julie Wilson; Robert E Denroche; Ilinca Lungu; John M S Bartlett; Faridah Mbabaali; Yosef Yarden; Nishanth Belugali Nataraj; Steven Gallinger; Raanan Berger
Journal:  Oncotarget       Date:  2017-06-20

9.  Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model.

Authors:  Kulthida Vaeteewoottacharn; Chawalit Pairojkul; Ryusho Kariya; Kanha Muisuk; Kanokwan Imtawil; Yaovalux Chamgramol; Vajarabhongsa Bhudhisawasdi; Narong Khuntikeo; Ake Pugkhem; O-Tur Saeseow; Atit Silsirivanit; Chaisiri Wongkham; Sopit Wongkham; Seiji Okada
Journal:  Cells       Date:  2019-05-23       Impact factor: 6.600

10.  Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients.

Authors:  Predrag Noveski; Svetlana Madjunkova; Emilija Sukarova Stefanovska; Nadica Matevska Geshkovska; Maja Kuzmanovska; Aleksandar Dimovski; Dijana Plaseska-Karanfilska
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.